SWOG clinical trial number
              SWOG-9051
          Pilot Evaluation of Combined Hepatic Chemoembolization and Systemic Chemotherapy with 5-FU and Folinic Acid for Metastatic Adenocarcinoma of the Colon and Rectum, Phase II
Closed
      
  Phase
              Accrual
  
                          
      100%
      
  
    Published
      
  Abbreviated Title
              Pilot Evaluation of Combined Hepatic Chemoembolization and Systemic Chemotherapy with 5-FU and Folinic Acid for Metastatic Adenocarcinoma of the Colon and Rectum, Phase II
          Activated
              04/15/1992
          Closed
              04/01/1995
          Research committees
Gastrointestinal Cancer
Publication Information Expand/Collapse
1999
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
1996
Combined hepatic chemoembolization (CE) and systemic continuous infusion 5-FU (CIFU) + leucovorin (LV) for metastatic colorectal cancer (MCC): A phase II Southwest Oncology Group trial.
Other Clinical Trials
SWOG Clinical Trial Number
              S2303
          Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
      
            Gastrointestinal Cancer
Activated
              05/06/2024
          Open
      
        
  SWOG Clinical Trial Number
              CTSU/A022101
          A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
      
            Gastrointestinal Cancer
Activated
              01/10/2023
          Open
      
  Phase
              SWOG Clinical Trial Number
              S2107
          Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
      
            Gastrointestinal Cancer
Activated
              06/06/2022
          Accrual
  
                          
      100%
      
  
    Open
      
  Phase